Introduction Boston Immune Technologies and Therapeutics, Inc. (BITT) is a company headquartered in Winchester, MA that specializes in the development of cancer immunotherapy. The company was established by Russell LaMontagne. BITT utilizes its proprietary DOMab platform to create a new class of antagonist antibodies that target TNF superfamily receptors. These antibodies are designed for use in various applications, including oncology, inflammation, autoimmunity, and infectious disease. BITT's lead candidate, BIR2101, is a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). |
Disease Domain | Count |
---|---|
Immune System Diseases | 4 |
Neoplasms | 2 |
Hemic and Lymphatic Diseases | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 4 |
Antibody | 2 |
Target |
Mechanism TNFR2 antagonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TNFR2 modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD40 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BITR-2101 ( TNFR2 ) | Peripheral T-Cell Lymphoma More | Phase 1 |
BITT-2101 ( TNFR2 ) | Recurrent Non-Hodgkin Lymphoma More | IND Approval |
CD30 targeting oncology program (BITT) ( CD30 ) | Neoplasms More | Preclinical |
BITT-CD4F10(Boston Immune Technologies and Therapeutics) ( CD40 ) | Autoimmune Diseases More | Preclinical |
BITT-CD4D11(Boston Immune Technologies and Therapeutics) ( CD40 ) | Autoimmune Diseases More | Preclinical |